Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Sato T, Butler MO, Piperno-Neumann S, Hassel JC, Nathan P, Shoushtari AN, Rutkowski P, Carvajal RD, Baurain JF, Schlaak M, Piulats JM, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Ikeguchi A, Joshua AM, Middleton MR, Edukulla R, Pfeiffer C, Sacco JJ

Open source

DOI: 10.1158/1078-0432.ccr-25-1513
Published: 2025 Dec 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-1513,
  title = {Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.},
  author = {Sato T and Butler MO and Piperno-Neumann S and Hassel JC and Nathan P and Shoushtari AN and Rutkowski P and Carvajal RD and Baurain JF and Schlaak M and Piulats JM and Sullivan RJ and Ochsenreither S and Dummer R and Kirkwood JM and Ikeguchi A and Joshua AM and Middleton MR and Edukulla R and Pfeiffer C and Sacco JJ},
  year = {2025},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-1513},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-1513}
}

RIS

TY  - JOUR
TI  - Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
AU  - Sato T
AU  - Butler MO
AU  - Piperno-Neumann S
AU  - Hassel JC
AU  - Nathan P
AU  - Shoushtari AN
AU  - Rutkowski P
AU  - Carvajal RD
AU  - Baurain JF
AU  - Schlaak M
AU  - Piulats JM
AU  - Sullivan RJ
AU  - Ochsenreither S
AU  - Dummer R
AU  - Kirkwood JM
AU  - Ikeguchi A
AU  - Joshua AM
AU  - Middleton MR
AU  - Edukulla R
AU  - Pfeiffer C
AU  - Sacco JJ
PY  - 2025
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-1513
UR  - https://doi.org/10.1158/1078-0432.ccr-25-1513
ER  -

APA

T, S., MO, B., S, P., JC, H., P, N., AN, S., P, R., RD, C., JF, B., M, S., JM, P., RJ, S., S, O., R, D., JM, K., A, I., AM, J., MR, M., R, E., C, P., & JJ, S. (2025). Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-1513

Source records

pubmed · retrieved 2026-09-27T06:23:30.478Z